Back to Journals » Therapeutics and Clinical Risk Management » Volume 10 » default

Therapeutics and Clinical Risk Management


Archive: Volume 10, 2014

Trabectedin for advanced soft tissue sarcomas: optimizing use

Reid A, Martin-Liberal J, Benson C

Therapeutics and Clinical Risk Management 2014, 10:1003-1011

Published Date: 12 December 2014

Prospective study of incidence and predictors of peripheral intravenous catheter-induced complications

Abolfotouh MA, Salam M, Bani-Mustafa A, White D, Balkhy HH

Therapeutics and Clinical Risk Management 2014, 10:993-1001

Published Date: 8 December 2014

Low perfusion index affects the difference in glucose level between capillary and venous blood

Acar N, Ozcelik H, Cevik AA, Ozakin E, Yorulmaz G, Kebapci N, Bilge U, Bilgin M

Therapeutics and Clinical Risk Management 2014, 10:985-991

Published Date: 20 November 2014

Vulnerable COPD patients with comorbidities: the role of roflumilast

Lipari M, Kale-Pradhan PB

Therapeutics and Clinical Risk Management 2014, 10:969-976

Published Date: 18 November 2014

Risk of Essure microinsert abdominal migration: case report and review of literature

Ricci G, Restaino S, Di Lorenzo G, Fanfani F, Scrimin F, Mangino FP

Therapeutics and Clinical Risk Management 2014, 10:963-968

Published Date: 17 November 2014

Cardiorenal syndrome type 2: from diagnosis to optimal management

De Vecchis R, Baldi C

Therapeutics and Clinical Risk Management 2014, 10:949-961

Published Date: 12 November 2014

Acceleration training for managing nonalcoholic fatty liver disease: a pilot study

Oh S, Shida T, Sawai A, Maruyama T, Eguchi K, Isobe T, Okamoto Y, Someya N, Tanaka K, Arai E, Tozawa A, Shoda J

Therapeutics and Clinical Risk Management 2014, 10:925-936

Published Date: 7 November 2014

Meta-analysis of oral contraceptives and rheumatoid arthritis risk in women

Qi S, Xin R, Guo WN, Liu Y

Therapeutics and Clinical Risk Management 2014, 10:915-923

Published Date: 4 November 2014

Clinical and economic studies of eptifibatide in coronary stenting [Corrigendum]

Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S

Therapeutics and Clinical Risk Management 2014, 10:913-914

Published Date: 28 October 2014

Engineering practice variation through provider agreement: a cluster-randomized feasibility trial

McCarren M, Twedt EL, Mansuri FM, Nelson PR, Peek BT

Therapeutics and Clinical Risk Management 2014, 10:905-912

Published Date: 28 October 2014

Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report

Ifteni P, Moga MA, Burtea V, Correll CU

Therapeutics and Clinical Risk Management 2014, 10:901-904

Published Date: 23 October 2014

Lobomycosis: epidemiology, clinical presentation, and management options

Francesconi VA, Klein AP, Santos AP, Ramasawmy R, Francesconi F

Therapeutics and Clinical Risk Management 2014, 10:851-860

Published Date: 9 October 2014

Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease

González-Pacheco H, Vargas-Barrón J, Vallejo M, Piña-Reyna Y, Altamirano-Castillo A, Sánchez-Tapia P, Martínez-Sánchez C

Therapeutics and Clinical Risk Management 2014, 10:815-823

Published Date: 6 October 2014

JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level

Lanzillo R, Liuzzi R, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia Morra V

Therapeutics and Clinical Risk Management 2014, 10:807-814

Published Date: 9 October 2014

The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU

Kunisawa T, Fujimoto K, Kurosawa A, Nagashima M, Matsui K, Hayashi D, Yamamoto K, Goto Y, Akutsu H, Iwasaki H

Therapeutics and Clinical Risk Management 2014, 10:797-806

Published Date: 4 October 2014

Effects of hyperbaric oxygenation therapy on symptomatic pneumocephalus

Paiva WS, Andrade AF, Figueiredo EG, Amorim RL, Prudente M, Teixeira MJ

Therapeutics and Clinical Risk Management 2014, 10:769-773

Published Date: 6 October 2014

Clinical management and therapeutic outcome of infertile couples in southeast Nigeria

Menuba IE, Ugwu EO, Obi SN, Lawani LO, Onwuka CI

Therapeutics and Clinical Risk Management 2014, 10:763-768

Published Date: 1 October 2014

Bloodstream infections in patients with hematological malignancies: which is more fatal – cancer or resistant pathogens?

Gedik H, Şimşek F, Kantürk A, Yildirmak T, Arica D, Aydin D, Demirel N, Yokuş O

Therapeutics and Clinical Risk Management 2014, 10:743-752

Published Date: 17 September 2014

Application of caspofungin in China compared with amphotericin B and fluconazole

Zhang CY, Cheng JY, Jiang Y, Liu JY

Therapeutics and Clinical Risk Management 2014, 10:737-741

Published Date: 10 September 2014

Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma

Hutajulu SH, Kurnianda J, Tan IB, Middeldorp JM

Therapeutics and Clinical Risk Management 2014, 10:721-736

Published Date: 5 September 2014

Magnetoledtherapy in the treatment of wounds after surgical procedures of the knee joint

Pasek J, Pasek T, Sieroń A

Therapeutics and Clinical Risk Management 2014, 10:717-720

Published Date: 2 September 2014

Emerging treatments in type 2 diabetes: focus on canagliflozin

Rosiak M, Grzeszczak S, Kosior DA, Postuła M

Therapeutics and Clinical Risk Management 2014, 10:683-689

Published Date: 21 August 2014

Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies

Patel NK, Finianos A, Whitaker KD, Aragon-Ching JB

Therapeutics and Clinical Risk Management 2014, 10:651-664

Published Date: 16 August 2014

The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions

Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castillo G, Giordano N, Nuti R

Therapeutics and Clinical Risk Management 2014, 10:641-650

Published Date: 13 August 2014

Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection

Molino CGRC, Carnevale RC, Rodrigues AT, Visacri MB, Moriel P, Mazzola PG

Therapeutics and Clinical Risk Management 2014, 10:631-639

Published Date: 7 August 2014

Double-balloon tamponade in the management of postpartum hemorrhage: a case series

Kavak SB, Kavak EC, Demirel I, Ilhan R

Therapeutics and Clinical Risk Management 2014, 10:615-620

Published Date: 2 August 2014

Clinical and economic studies of eptifibatide in coronary stenting

Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S

Therapeutics and Clinical Risk Management 2014, 10:603-614

Published Date: 2 August 2014

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline

Leibert E, Danckers M, Rom WN

Therapeutics and Clinical Risk Management 2014, 10:597-602

Published Date: 29 July 2014

Optimal management of renal artery fibromuscular dysplasia

Gottsäter A, Lindblad B

Therapeutics and Clinical Risk Management 2014, 10:583-595

Published Date: 28 July 2014

HIV-associated lipodystrophy: a review from a Brazilian perspective

Alves MD, Brites C, Sprinz E

Therapeutics and Clinical Risk Management 2014, 10:559-566

Published Date: 17 July 2014

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

Konya H, Yano Y, Matsutani S, Tsunoda T, Ikawa T, Kusunoki Y, Matsuo T, Miuchi M, Katsuno T, Hamaguchi T, Miyagawa JI, Namba M

Therapeutics and Clinical Risk Management 2014, 10:547-558

Published Date: 11 July 2014

Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice

Lozano-Blázquez A, Calvo-Pita C, Carbajales-Álvarez M, Suárez-Gil P, Martínez-Martínez F, Calleja-Hernández MA

Therapeutics and Clinical Risk Management 2014, 10:527-535

Published Date: 9 July 2014

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection

Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G

Therapeutics and Clinical Risk Management 2014, 10:493-504

Published Date: 26 June 2014

Icosapent ethyl for the treatment of severe hypertriglyceridemia

Fares H, Lavie CJ, DiNicolantonio JJ, O’Keefe JH, Milani RV

Therapeutics and Clinical Risk Management 2014, 10:485-492

Published Date: 24 June 2014

Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women

Papaleo E, Alviggi C, Colombo GL, Pisanelli C, Ripellino C, Longobardi S, Canonico PL

Therapeutics and Clinical Risk Management 2014, 10:479-484

Published Date: 25 June 2014

Managing an outpatient parenteral antibiotic therapy team: challenges and solutions

Halilovic J, Christensen CL, Nguyen HH

Therapeutics and Clinical Risk Management 2014, 10:459-465

Published Date: 18 June 2014

Nature and frequency of medication errors in a geriatric ward: an Indonesian experience

Ernawati DK, Lee YP, Hughes JD

Therapeutics and Clinical Risk Management 2014, 10:413-421

Published Date: 3 June 2014

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir

Kanda T, Nakamoto S, Wu S, Yokosuka O

Therapeutics and Clinical Risk Management 2014, 10:387-394

Published Date: 24 May 2014

Radiation dose to the nodal regions during prone versus supine breast irradiation

Csenki M, Újhidy D, Cserháti A, Kahán Z, Varga Z

Therapeutics and Clinical Risk Management 2014, 10:367-372

Published Date: 21 May 2014

Rheumatoid arthritis in Jordan: a cross sectional study of disease severity and associated comorbidities

Alawneh KM, Khassawneh BY, Ayesh MH, Smadi M

Therapeutics and Clinical Risk Management 2014, 10:363-366

Published Date: 19 May 2014

Management of malignant hyperthermia: diagnosis and treatment

Schneiderbanger D, Johannsen S, Roewer N, Schuster F

Therapeutics and Clinical Risk Management 2014, 10:355-362

Published Date: 14 May 2014

Udenafil for the treatment of erectile dysfunction

Cho MC, Paick JS

Therapeutics and Clinical Risk Management 2014, 10:341-354

Published Date: 14 May 2014

Experimental study of tissue-engineered cartilage allograft with RNAi chondrocytes in vivo

Wang ZH, Li XL, He XJ, Zhang XH, Yang ZQ, Xu M, Wu BJ, Tu JB, Luo HN, Yan J

Therapeutics and Clinical Risk Management 2014, 10:335-340

Published Date: 8 May 2014

Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage

Gedik H, Şimşek F, Yıldırmak T, Kantürk A, Arıca D, Aydın D, Demirel N, Yokuş O

Therapeutics and Clinical Risk Management 2014, 10:305-312

Published Date: 28 April 2014

Acute-on-chronic liver failure: a review

Zamora Nava LE, Aguirre Valadez J, Chávez-Tapia NC, Torre A

Therapeutics and Clinical Risk Management 2014, 10:295-303

Published Date: 23 April 2014

Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls

Gao J, Kang AJ, Lin S, Dai ZJ, Zhang SQ, Liu D, Zhao Y, Yang PT, Wang M, Wang XJ

Therapeutics and Clinical Risk Management 2014, 10:269-277

Published Date: 15 April 2014

Prediction and prevention of the first psychotic episode: new directions and opportunities

Piras S, Casu G, Casu MA, Orrù A, Ruiu S, Pilleri A, Manca G, Marchese G

Therapeutics and Clinical Risk Management 2014, 10:241-253

Published Date: 28 March 2014

Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns

Gao CH, Yu LS, Zeng S, Huang YW, Zhou Q

Therapeutics and Clinical Risk Management 2014, 10:217-227

Published Date: 27 March 2014

“Denervation” of autonomous nervous system in idiopathic pulmonary arterial hypertension by low-dose radiation: a case report with an unexpected outcome

Hohenforst-Schmidt W, Zarogoulidis P, Oezkan F, Mahnkopf C, Grabenbauer G, Kreczy A, Bartunek R, Darwiche K, Freitag L, Li Q, Huang H, Vogl T, LePilvert P, Tsiouda T, Tsakiridis K, Zarogoulidis K, Brachmann J

Therapeutics and Clinical Risk Management 2014, 10:207-215

Published Date: 27 March 2014

Medication transitions and polypharmacy in older adults following acute care

Gamble JM, Hall JJ, Marrie TJ, Sadowski CA, Majumdar SR, Eurich DT

Therapeutics and Clinical Risk Management 2014, 10:189-196

Published Date: 19 March 2014

Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus

Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA

Therapeutics and Clinical Risk Management 2014, 10:173-188

Published Date: 20 March 2014

Is hypertriglyceridemia a prognostic factor in sepsis?

Cetinkaya A, Erden A, Avci D, Karagoz H, Karahan S, Basak M, Bulut K, Gencer V, Mutlu H

Therapeutics and Clinical Risk Management 2014, 10:147-150

Published Date: 27 February 2014

Hypoxic hepatitis in cardiac intensive care unit: a study of cardiovascular risk factors, clinical course, and outcomes

Chávez-Tapia NC, Balderas-Garces BV, Meza-Meneses P, Herrera-Gomar M, García-López S, Gónzalez-Chon O, Uribe M

Therapeutics and Clinical Risk Management 2014, 10:139-145

Published Date: 25 February 2014

Pharmacy students' attitudes toward pharmaceutical care in Qatar

El Hajj MS, Hammad AS, Afifi HM

Therapeutics and Clinical Risk Management 2014, 10:121-129

Published Date: 18 February 2014

Postural pattern recognition in children with unilateral cerebral palsy

Domagalska-Szopa M, Szopa A

Therapeutics and Clinical Risk Management 2014, 10:113-120

Published Date: 17 February 2014

Actual preoperative fasting time in Brazilian hospitals: the BIGFAST multicenter study

Aguilar-Nascimento JE, Almeida Dias AL, Dock-Nascimento DB, Correia MITD, Campos ACL, Portari-Filho PE, Oliveira SS

Therapeutics and Clinical Risk Management 2014, 10:107-112

Published Date: 14 February 2014

Active axial spondyloarthritis: potential role of certolizumab pegol

Ranatunga S, Miller AV

Therapeutics and Clinical Risk Management 2014, 10:87-94

Published Date: 12 February 2014

Clinical differences between H3N2 and H1N1 influenza 2012 and lower respiratory tract infection found using a statistical classification approach

Petridis D, Zarogoulidis P, Kallianos A, Kioumis I, Trakada G, Spyratos D, Papaiwannou A, Porpodis K, Huang H, Rapti A, Hohenforst-Schmidt W, Zarogoulidis K

Therapeutics and Clinical Risk Management 2014, 10:77-86

Published Date: 7 February 2014

Risk factors for an early dialysis start in patients with diabetic nephropathy end-stage renal disease

Mizuno T, Hayashi T, Kato R, Noguchi A, Hayashi H, Yuzawa Y, Yamada S, Nagamatsu T

Therapeutics and Clinical Risk Management 2014, 10:73-76

Published Date: 30 January 2014

Risk factors for mortality in Asian Taiwanese patients with methanol poisoning

Lee CY, Chang EK, Lin JL, Weng CH, Lee SY, Juan KC, Yang HY, Lin C, Lee SH, Wang IK, Yen TH

Therapeutics and Clinical Risk Management 2014, 10:61-67

Published Date: 17 January 2014

Frequency of tuberculosis among diabetic patients in the People's Republic of China

Wang HT, Zhang J, Ji LC, You SH, Bai Y, Dai W, Wang ZY

Therapeutics and Clinical Risk Management 2014, 10:45-49

Published Date: 10 January 2014

Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy

Dang Y, Sun X, Xu Y, Mu Y, Zhao M, Zhao J, Zhu Y, Zhang C

Therapeutics and Clinical Risk Management 2014, 10:37-43

Published Date: 9 January 2014

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting

Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A

Therapeutics and Clinical Risk Management 2014, 10:9-15

Published Date: 18 December 2013